Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Drugs & Aging
Published in: Drugs & Aging 6/2005

01-06-2005 | Original Research Article

Clinical Assessment of Effects of Botanical Supplementation on Cytochrome P450 Phenotypes in the Elderly

St John’s Wort, Garlic Oil, Panax ginseng and Ginkgo biloba

Authors: Dr Bill J. Gurley, Stephanie F. Gardner, Martha A. Hubbard, D. Keith Williams, W. Brooks Gentry, Yanyan Cui, Catharina Y. W. Ang

Published in: Drugs & Aging | Issue 6/2005

Login to get access

Abstract

Objectives

Elderly patients are more likely to ingest prescription medications concurrently with botanical supplements, and may therefore be vulnerable to herb-drug interactions. Phytochemical-mediated modulation of cytochrome P450 (CYP) activity may underlie many herb-drug interactions. Some evidence suggests that CYP activity may decrease in the elderly. If so, herb-mediated changes in CYP activity may take on greater clinical relevance in this population. In this study, single timepoint, phenotypic metabolic ratios were used to determine whether long-term supplementation of St John’s wort, garlic oil, Panax ginseng, and Ginkgo biloba affected CYP1A2, CYP2D6, CYP2E1 or CYP3A4 activity in elderly subjects.

Methods

Twelve healthy volunteers between the ages of 60 and 76 years (mean age 67 years) were randomly assigned to receive each botanical supplement for 28 days followed by a 30-day washout period. Probe drug cocktails of midazolam, caffeine, chlorzoxazone and debrisoquine were administered before and at the end of supplementation. Pre- and post-supplementation phenotypic ratios were determined for CYP3A4, CYP1A2, CYP2E1 and CYP2D6 using 1-hydroxymidazolam/midazolam serum ratios (1-hour), paraxanthine/caffeine serum ratios (6-hour), 6-hydroxychlorzoxazone/chlorzoxazone serum ratios (2-hour) and debrisoquine urinary recovery ratios (8-hour), respectively. The content of purported ‘active’ phytochemicals was determined for each supplement.

Results

Comparisons of pre- and post-St John’s wort phenotypic ratios revealed significant induction of CYP3A4 (≈140%) and CYP2E1 activity (≈28%). Garlic oil inhibited CYP2E1 activity by approximately 22%. P. ginseng inhibition of CYP2D6 was statistically significant, but the magnitude of the effect (≈7%) did not appear to be clinically relevant. None of the supplements tested in this study appeared to affect CYP1A2 activity.

Conclusions

Elderly subjects, like their younger counterparts, are susceptible to herb-mediated changes in CYP activity, especially those involving St John’s wort. Pharmacokinetic herb-drug interactions stemming from alterations in CYP activity may adversely affect drug efficacy and/or toxicity. When compared with earlier studies that employed young subjects, the data suggest that some age-related changes in CYP responsivity to botanical supplementation may exist. Concomitant ingestion of botanical supplements with prescription medications, therefore, should be strongly discouraged in the elderly.
Footnotes
1
The use of trade names is for product identification purposes only and does not imply endorsement.
 
Literature
1.
Eisenberg DM, Davis RB, Ettner SL, et al. Trends in alternative medicine use in the United States, 1990–1997: results of a follow-up national survey. JAMA 1998; 280: 1569–75PubMedCrossRef
2.
Klepser TB, Doucette WR, Horton MR, et al. Assessment of patient’s perceptions and beliefs regarding herbal therapies. Pharmacotherapy 2000; 20: 83–7PubMedCrossRef
3.
Kaufman DW, Kelly JP, Rosenberg L, et al. Recent patterns of medication use in the ambulatory adult population of the United States. JAMA 2002; 287: 337–44PubMedCrossRef
4.
Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drugs: a systematic review. Drugs 2001; 61: 2163–75PubMedCrossRef
5.
6.
Brazier NC, Levine MAH. Drug-herb interaction among commonly used conventional medicines: a compendium for health care professionals. Am J Ther 2003; 10: 163–9PubMedCrossRef
7.
Gurley BJ, Hagan DW. Herbal and dietary supplement interactions with drugs. In: McCabe BJ, Frankel EH, Wolfe JJ, editors. Handbook of food-drug interactions. Boca Raton: CRC Press, 2003: 259–293
8.
9.
Gunther S, Patterson RE, Kristal AR, et al. Demographic and health-related correlates of herbal and specialty supplement use. J Am Diet Assoc 2004; 104: 27–34PubMedCrossRef
10.
Skinner CM, Rangasami J. Preoperative use of herbal medicines: a patient survey. Br J Anaesth 2002; 89: 792–5PubMedCrossRef
11.
Rhee SM, Garg VK, Hershey CO. Use of complementary and alternative medicines by ambulatory patients. Arch Intern Med 2004; 164: 1004–9PubMedCrossRef
12.
Adusumilli PS, Ben-Porat L, Pereira M, et al. The prevalence and predictors of herbal medicine use in surgical patients. J Am Coll Surg 2004; 198: 583–90PubMedCrossRef
13.
Foster DF, Phillips RS, Hamel B. Alternative medicine use in older Americans. J Am Geriatr Soc 2000; 48: 1560–5PubMed
14.
Cohen RJ, Ek K, Pan CX. Complementary and alternative medicine (CAM) use by older adults: a comparison of self-report and physician chart documentation. J Gerontol 2002; 57A: M223–7
15.
Dergal JM, Gold JL, Laxer DA, et al. Potential interactions between herbal medicines and conventional drug therapies used by older adults attending a memory clinic. Drugs Aging 2002; 19: 879–86PubMedCrossRef
16.
Wang Z, Gorski JC, Hamman MA, et al. The effects of St John’s wort (Hypericum perforatum) on human cytochrome P450 activity. Clin Pharmacol Ther 2001; 70: 317–26PubMed
17.
Gurley BJ, Gardner SF, Hubbard MA, et al. Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans. Clin Pharmacol Ther 2002; 72: 276–82PubMedCrossRef
18.
Markowitz JS, Donovan JL, DeVane CL, et al. Multiple-dose administration of Ginkgo biloba did not affect cytochrome P-450 2D6 or 3A4 activity in normal volunteers. J Clin Psychopharmacol 2003; 23: 576–81PubMedCrossRef
19.
Markowitz JS, DeVane CL, Chavin KD, et al. Effects of garlic (Allium sativum L.) supplementation on cytochrome P450 2D6 and 3A4 activity in healthy volunteers. Clin Pharmacol Ther 2003; 74: 170–7PubMedCrossRef
20.
Anderson GD, Rosito G, Mohustsy MA, et al. Drug interaction potential of soy extract and Panax ginseng. J Clin Pharmacol 2003; 43: 643–8PubMed
21.
Gorski JC, Huang S-M, Pinto A, et al. The effect of Echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. Clin Pharmacol Ther 2004; 75: 89–100PubMedCrossRef
22.
Wentworth JM, Agostini M, Love J, et al. St John’s wort, a herbal antidepressant, activates the steroid X receptor. J Endocrinol 2000; 166: R11–6PubMedCrossRef
23.
Moore LB, Goodwin B, Jones SA, et al. St John’s wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci U S A 2000; 97: 7500–2PubMedCrossRef
24.
Piscitelli SC, Burstein AH, Weiden N, et al. The effect of garlic supplements on the pharmacokinetics of saquinavir. Clin Infect Dis 2002; 34: 234–8PubMedCrossRef
25.
26.
Kales HC, Blow FC, Welsh DE, et al. Herbal products and other supplements: use by elderly veterans with depression and dementia and their caregivers. J Geriatr Psychiatry Neurol 2004; 17: 25–31PubMedCrossRef
27.
Anderson GD, Rosito G, Mohustsy MA, et al. Drug interaction potential of soy extract and Panax ginseng. J Clin Pharmacol 2003; 43: 643–8PubMed
28.
Kinirons MT, Crome P. Clinic pharmacokinetic considerations in the elderly. Clin Pharmacokinet 1997; 33: 302–12PubMedCrossRef
29.
Tanaka E. In vivo age-related changes in hepatic drug-oxidizing capacity in humans. J Clin Pharm Ther 1998; 23: 247–55PubMedCrossRef
30.
McLean AJ, Le Couteur DG. Aging biology and geriatric clinical pharmacology. Pharmacol Rev 2004; 56: 163–84PubMedCrossRef
31.
Fuhr U, Rost KL. Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and in saliva. Pharmacogenetics 1994; 4: 109–16PubMedCrossRef
32.
Frye RF, Matzke GR, Adedoyin A, et al. Validation of the five-drug ‘Pittsburgh cocktail’ approach for assessment of selective regulation of drug-metabolizing enzymes. Clin Pharmacol Ther 1997; 62: 365–76PubMedCrossRef
33.
Streetman DS, Bertino JS, Nafziger AN. Phenotyping of drug metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics 2000; 10: 187–216PubMedCrossRef
34.
Gurley BJ, Gardner SF, Hubbard MA, et al. In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: Citrus aurantium, Echinacea purpurea, milk thistle, and saw palmetto. Clin Pharmacol Ther 2004; 76: 428–40PubMedCrossRef
35.
Palmer JL, Scott RJ, Gibson A, et al. An interaction between cytochrome P450 probe substrates chlorzoxazone (CYP2E1) and midazolam (CYP3A). Br J Clin Pharmacol 2001; 52: 555–61PubMedCrossRef
36.
Holland DT, Godfredsen KA, Page T, et al. Simple high performance liquid chromatography method for the simultaneous determination of serum caffeine and paraxanthine following rapid sample preparation. J Chromatogr B Biomed Sci Appl 1998; 707: 105–10PubMedCrossRef
37.
Frye RF, Stiff DD. Determination of chlorzoxazone and 6-hydroxychlorzoxazone in human plasma and urine by high-performance liquid chromatography. J Chromatogr B Biomed Appl 1996; 686: 291–6PubMedCrossRef
38.
Frye RF, Branch RA. Improved high-performance liquid Chromatographic determination of debrisoquine and 4-hydroxydebrisoquin in human urine following direct injection. J Chromatogr B Biomed Appl 1996; 677: 178–82PubMedCrossRef
39.
Sautou V, Chopineau J, Terrisse MP, et al. Solid-phase extraction of midazolam and two of its metabolites from plasma for high performance liquid Chromatographic analysis. J Chromatogr 1991; 571: 298–304PubMedCrossRef
40.
Liu FF, Ang CYW, Heinze TM, et al. Evaluation of major active components in St. John’s wort dietary supplements by high-performance liquid chromatography with photodiode array detection and electrospray mass spectrometric confirmation. J Chromatogr A 2000; 888: 85–92PubMedCrossRef
41.
Cui Y, Gurley B, Ang CYW, et al. Determination of hyperforin in human plasma using solid-phase extraction and high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Analyt Technol Biomed Life Sci 2002; 780: 129–35PubMedCrossRef
42.
Lawson L, Wang Z, Hughes BG. Identification and HPLC quantitation of the Sulfides and dialk(en)yl thiosulfinates in commercial garlic products. Planta Med 1991; 57: 363–70PubMedCrossRef
43.
Li W, Fitzloff JF. Simultaneous determination of terpene lactones and flavonoid aglycones in Ginkgo biloba by high-performance liquid chromatography with evaporative light scattering detection. J Pharm Biomed Anal 2002; 30: 67–75PubMedCrossRef
44.
Zhu B, Ou-Yang DS, Cheng Z, et al. Single plasma sampling to predict oral clearance of CYP3A probe midazolam. Acta Pharmacol Sin 2001; 22: 634–8PubMed
45.
Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Mahwah (NJ): Lawrence Erlbaum Associates Publishers, 1988: 19–42
46.
Gurley BJ, Gardner SF, Hubbard MA, et al. In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4 phenotypes. Clin Pharmacol Ther 2005. In press
47.
De Los Reyes GC, Koda RT. Determining hyperforin and hypericin content in eight brands of St. John’s wort. Am J Health Syst Pharm 2002; 59: 545–7
48.
Ganzera M, Zhao J, Khan IA. Hypericum perforatum: chemical profiling and quantitative results of St John’s wort products by an improved high-performance liquid chromatography method. J Pharm Sci 2002; 91: 623–30PubMedCrossRef
49.
Wurglics M, Westerhoff K, Kaunzinger A, et al. Batch-to-batch reproducibility of St John’s wort preparations. Pharmacopsychiatry 2001; 34Suppl. 1: S152–6PubMedCrossRef
50.
Hunt CM, Strater S, Stave GM. Effect of normal aging on the activity of human hepatic cytochrome P450IIE1. Biochem Pharmacol 1990; 40: 1666–9PubMedCrossRef
51.
52.
Koop DR, Tierney DJ. Multiple mechanisms in the regulation of ethanol-inducible cytochrome P450IIE1. Bioessays 1990; 12: 429–35PubMedCrossRef
53.
Chien JY, Thummel KE, Slattery JT. Pharmacokinetic consequences of induction of CYP2E1 by ligand stabilization. Drug Metab Dispos 1997; 25: 1165–75PubMed
54.
55.
Loizou GD, Crocker J. The effects of alcohol and diallyl sulphide on CYP2E1 activity in humans: a phenotyping study using chlorzoxazone. Hum Exp Toxicol 2001; 20: 321–7PubMedCrossRef
56.
Haber D, Siess M, Canivenc-Lavier M, et al. Differential effects of dietary diallyl sulfide and diallyl disulfide on rat intestinal and hepatic drug-metabolizing enzymes. J Toxicol Environ Health 1995; 44: 423–34PubMedCrossRef
57.
Siess M, Le Bon A, Canivenc-Lavier M, et al. Modification of hepatic drug-metabolizing enzymes in rats treated with alkyl sulfides. Cancer Lett 1997; 120: 195–201PubMedCrossRef
58.
Yang CS, Chhabra SK, Hong J, et al. Mechanisms of inhibition of chemical toxicity and carcinogenesis by diallyl sulfide (DAS) and related compounds from garlic. J Nutr 2001; 131: 1041S–5SPubMed
59.
Chung KF, Dent G, McCuster M, et al. Effect of ginkgolide mixture (BN 52063) in antagonizing skin and platelet responses to platelet activating factor in man. Lancet 1987; I: 248–51CrossRef
60.
Duche JC, Barre J, Guinot P, et al. Effect of Ginkgo biloba extract on microsomal enzyme induction. Int J Clin Pharm Res 1989; 9: 165–8
61.
Janetzky K, Morreale AP. Probable interaction between warfarin and ginseng. Am J Health Syst Pharm 1997; 54: 692–3PubMed
62.
Yuan C-S, Wei G, Dey L, et al. American ginseng reduces warfarin’s effect in healthy patients: a randomized controlled trial. Ann Intern Med 2004; 141: 23–7PubMed
Metadata
Title
Clinical Assessment of Effects of Botanical Supplementation on Cytochrome P450 Phenotypes in the Elderly
St John’s Wort, Garlic Oil, Panax ginseng and Ginkgo biloba
Authors
Dr Bill J. Gurley
Stephanie F. Gardner
Martha A. Hubbard
D. Keith Williams
W. Brooks Gentry
Yanyan Cui
Catharina Y. W. Ang
Publication date
01-06-2005
Publisher
Springer International Publishing
Published in
Drugs & Aging / Issue 6/2005
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI
https://doi.org/10.2165/00002512-200522060-00006

Other articles of this Issue 6/2005

Drugs & Aging 6/2005 Go to the issue

Review Article

Poststroke Dementia in the Elderly

Review Article

Reducing the Risk of Stroke in Elderly Patients with Hypertension

Leading Article

Adenosine A2A Receptor Antagonists for Parkinson’s Disease

Leading Article

Late-Onset Ankylosing Spondylitis and Related Spondylarthropathies

Review Article

Influenza Vaccination in the Elderly
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits